Neurocrine Biosciences, Inc. (NBIX) Q4 2015 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Up 4.96%

Neurocrine Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising nearly 5%. The management's focus on advancing their pipeline suggests potential for future growth, although no specific guidance was given for upcoming quarters.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.34	N/A	+3.68%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their future projects. They emphasized their commitment to innovation and growth.

Management highlighted ongoing efforts to advance pipeline programs.

They expressed confidence in achieving future milestones despite current losses.

Neurocrine Biosciences Beats on EPS, Stock Up 4.96%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Up 4.96%

Key numbers

Management commentary